How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

450 results for

Dermal Filler Injection

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. In vivo Bio-Integration of Three Hyaluronic Acid Fillers in Human Skin: A Histological Study. Full Text available with Trip Pro

In vivo Bio-Integration of Three Hyaluronic Acid Fillers in Human Skin: A Histological Study. Hyaluronic acid (HA) formulations are used for aesthetic applications. Different cross-linking technologies result in HA dermal fillers with specific characteristic visco-elastic properties.Bio-integration of three CE-marked HA dermal fillers, a cohesive (monophasic) polydensified, a cohesive (monophasic) monodensified and a non-cohesive (biphasic) filler, was analysed with a follow-up of 114 days (...) after injection. Our aim was to study the tolerability and inflammatory response of these fillers, their patterns of distribution in the dermis, and influence on tissue integrity.Three HA formulations were injected intradermally into the iliac crest region in 15 subjects. Tissue samples were analysed after 8 and 114 days by histology and immunohistochemistry, and visualized using optical and transmission electron microscopy.Histological results demonstrated that the tested HA fillers showed specific

2014 Dermatology

122. Nonsurgical periocular rejuvenation: advanced cosmetic uses of neuromodulators and fillers. (Abstract)

Nonsurgical periocular rejuvenation: advanced cosmetic uses of neuromodulators and fillers. To review the current literature regarding aesthetic enhancement using facial neuromodulators and fillers and to present advanced techniques using facial injectables for periocular rejuvenation.The authors provide a summary of traditional periocular locations for the injection of neuromodulators and dermal fillers. The authors also present novel and advanced techniques utilizing injectables (...) in the periocular region.Minimally invasive procedures with little-to-no recovery time are continuing to increase in popularity. Neuromodulators and hyaluronic acid gel fillers have been shown to be well tolerated and efficacious nonsurgical alternatives in periocular rejuvenation.

2014 Current Opinion in Ophthalmology

123. Cosmetic Facial Fillers and Severe Vision Loss. Full Text available with Trip Pro

Cosmetic Facial Fillers and Severe Vision Loss. Dermal injection of cosmetic fillers can lead to irreversible blindness when injected in the forehead, and this possible adverse effect is not typically mentioned to patients.Vision loss from central retinal artery occlusion occurring, after cosmetic facial enhancement, was irreversible in 3 patients. However, 1 patient had a small amount of recovery with aggressive therapy.Cosmetic facial fillers are not approved for use in the forehead, but off (...) -label use for enhancement in this region is common. To our knowledge, there have been no prior reports of blindness caused by filler injected into the forehead. We present findings of central retinal artery occlusion due to fillers in 3 patients shortly after their cosmetic procedures. The filler presumably enters the central retinal artery via the rich external-internal carotid anastomoses and becomes embedded in the retinal tissues, potentially leading to irreversible and severe vision loss

2014 JAMA ophthalmology

124. Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

glabellar frown lines Female or male, 30 to 65 years of age in good general health Women of childbearing potential must agree to use an effective method of birth control during the course of the study Willing to refrain from receipt of facial fillers, laser treatments or use of products that affect skin remodeling and causes an active dermal response Exclusion Criteria: Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A such as amyotrophic (...) Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2014 Clinical Trials

125. Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines

course of the study Exclusion Criteria (A subject must not meet the following exclusion criteria in order to be eligible for enrollment in the stud)y: Previous treatment with botulinum toxin of any serotype in the forehead area within the last 8 months Previous treatment with any facial aesthetic procedure (e.g. injection with fillers, chemical peeling, photo rejuvenation) in the glabellar area within the last 12 months Previous insertion of permanent material in the glabellar area Planned treatment (...) of the lateral canthus (subjects can continue with their usual skin care routine) Inability to substantially lessen glabellar frown lines even by physically spreading them apart Marked facial asymmetry Ptosis of eyelid and/or eyebrow, or history of eyelid and/or eyebrow ptosis History of facial nerve palsy Excessive dermatochalasis, deep dermal scarring, thick sebaceous skin Any active infection in the area of the injection sites Medical condition that may affect neuromuscular function (e.g., myasthenia

2014 Clinical Trials

126. Injectable Bulking Agents for Incontinence (Diagnosis)

to intrinsic sphincter deficiency by artificially inflating the submucosal tissues of the bladder neck and urethra. These procedures involve injecting synthetic and autologous fillers into the wall of the urethra to aid in coaptation of the mucosa. Bulking the bladder neck with particulate matter effectively closes the lumen of the urethra by improving urethral coaptation and restores the mucosal seal mechanism of continence. However, issues with migration, leakage, and resorption of injected agents (...) R, Koduri S, Thomson RB, Schwabe L, Sand PK. Is it safe to reuse a syringe of glutaraldehyde cross-linked collagen? A microbiological study. J Urol . 2000 Oct. 164(4):1275-6. . Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology . 2007 May. 69(5):876-80. . Lightner D, Calvosa C, Andersen R. A new injectable bulking agent

2014 eMedicine.com

127. Injectable Bulking Agents for Incontinence (Overview)

to intrinsic sphincter deficiency by artificially inflating the submucosal tissues of the bladder neck and urethra. These procedures involve injecting synthetic and autologous fillers into the wall of the urethra to aid in coaptation of the mucosa. Bulking the bladder neck with particulate matter effectively closes the lumen of the urethra by improving urethral coaptation and restores the mucosal seal mechanism of continence. However, issues with migration, leakage, and resorption of injected agents (...) R, Koduri S, Thomson RB, Schwabe L, Sand PK. Is it safe to reuse a syringe of glutaraldehyde cross-linked collagen? A microbiological study. J Urol . 2000 Oct. 164(4):1275-6. . Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology . 2007 May. 69(5):876-80. . Lightner D, Calvosa C, Andersen R. A new injectable bulking agent

2014 eMedicine.com

128. Injectable Bulking Agents for Incontinence (Treatment)

to intrinsic sphincter deficiency by artificially inflating the submucosal tissues of the bladder neck and urethra. These procedures involve injecting synthetic and autologous fillers into the wall of the urethra to aid in coaptation of the mucosa. Bulking the bladder neck with particulate matter effectively closes the lumen of the urethra by improving urethral coaptation and restores the mucosal seal mechanism of continence. However, issues with migration, leakage, and resorption of injected agents (...) R, Koduri S, Thomson RB, Schwabe L, Sand PK. Is it safe to reuse a syringe of glutaraldehyde cross-linked collagen? A microbiological study. J Urol . 2000 Oct. 164(4):1275-6. . Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology . 2007 May. 69(5):876-80. . Lightner D, Calvosa C, Andersen R. A new injectable bulking agent

2014 eMedicine.com

129. Injectable Bulking Agents for Incontinence (Follow-up)

to intrinsic sphincter deficiency by artificially inflating the submucosal tissues of the bladder neck and urethra. These procedures involve injecting synthetic and autologous fillers into the wall of the urethra to aid in coaptation of the mucosa. Bulking the bladder neck with particulate matter effectively closes the lumen of the urethra by improving urethral coaptation and restores the mucosal seal mechanism of continence. However, issues with migration, leakage, and resorption of injected agents (...) R, Koduri S, Thomson RB, Schwabe L, Sand PK. Is it safe to reuse a syringe of glutaraldehyde cross-linked collagen? A microbiological study. J Urol . 2000 Oct. 164(4):1275-6. . Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology . 2007 May. 69(5):876-80. . Lightner D, Calvosa C, Andersen R. A new injectable bulking agent

2014 eMedicine.com

130. Collagen Injections

A, Hurwitz D, Ronel D. Malar augmentation with a polymethylmethacrylate-enhanced filler: assessment of a 12-month open-label pilot study. Aesthet Surg J . 2013 Mar. 33(3):421-30. . The American Society for Aesthetic Plastic Surgery Cosmetic Surgery National Data Bank Statistics. 2012; Jeong SH, Fan YF, Baek JU, et al. Long-lasting and bioactive hyaluronic acid-hydroxyapatite composite hydrogels for injectable dermal fillers: Physical properties and in vivo durability. J Biomater Appl . 2016 Sep. 31 (3 (...) , Zachary CB. Quality of life outcomes associated with treatment of human immunodeficiency virus (HIV) facial lipoatrophy. Int J Dermatol . 2016 Dec. 55 (12):1311-20. . Restylane Lyft with Lidocaine Injectable Gel Injectable Dermal Filler - P040024/S073. US Food and Drug Administration. Available at . Accessed: Oct 26, 2017. Hyaluronic Acid Wrinkle Treatments. Restylane Products. Available at . Accessed: Oct 26, 2017. Lacombe V. Sculptra: a stimulatory filler. Facial Plast Surg . 2009 May. 25(2):95-9

2014 eMedicine Surgery

131. Clinical comparison of two hyaluronic acid-derived fillers in the treatment of nasolabial folds: Mesoglow® and IAL System®. (Abstract)

Clinical comparison of two hyaluronic acid-derived fillers in the treatment of nasolabial folds: Mesoglow® and IAL System®. Hyaluronic acid (HA) dermal fillers are widely used to reduce the appearance of aging. However, comparative research on the efficacy and safety of products of similar composition is limited. We compared outcomes achieved with two non-cross-linked HA fillers of almost identical composition, Mesoglow® and IAL System® . Forty subjects with visible nasolabial folds (NLFs (...) ) were enrolled in a randomized study. Wrinkle severity was rated using the 5-point Wrinkle Severity Rating Scale (WSRS). Each subject was injected with Mesoglow® in one NLF and IAL System® in the other. An optimal cosmetic result was established at two weeks after a second treatment. Participants were then reassessed at 2, 6, and 12 weeks, respectively, post-optimal cosmetic result using the WSRS. The degree of improvement was also assessed by subjects and investigators using the Global Aesthetic

2012 International journal of dermatology Controlled trial quality: uncertain

132. Full-Face Rejuvenation Using a Range of Hyaluronic Acid Fillers: Efficacy, Safety, and Patient Satisfaction over 6 Months. (Abstract)

Full-Face Rejuvenation Using a Range of Hyaluronic Acid Fillers: Efficacy, Safety, and Patient Satisfaction over 6 Months. Full-face rejuvenation with dermal fillers in patients with multiple aesthetic indications is rarely studied.To assess whether a new range of hyaluronic acid filler is suitable for full-face rejuvenation and to evaluate efficacy, safety, and patient satisfaction.In this 6-month study, participants could receive five different fillers from the same range (HA(E) )for up (...) to eight indications (periorbital lines, tear troughs, cheeks, cheek folds, nasolabial folds, upper lip lines, lips, and marionette lines). Outcomes included global aesthetic improvement, improvement in each indication, adverse events, local tolerability, and satisfaction.Seventy-seven participants with a mean age of 54.5 were enrolled; 48.1% had five or more indications treated. Mean total injection volume (baseline and touch-up) per participant was 6.7 mL. At month 6, 92.1% of participants remained

2012 Dermatologic Surgery

133. Autologous injectable dermis: a clinical and histological study. (Abstract)

Autologous injectable dermis: a clinical and histological study. No perfect solution yet exists for dermal fillers. The authors hypothesized that autologous dermis can be processed in an operator-friendly manner and adopted in selected patients as a filler, following the principle of replacing "like with like."The authors designed a prototype "cutting chamber" to morsel dermis into an injectable form. Autologous injectable dermis grafting was performed in 16 patients who underwent lip (...) reported transient palpable firmness for the first 6 months, which subsequently resolved. Histological examination of processed and injected dermis showed volume maintenance over time, effective revascularization of the mass, and structural reorganization with collagen bundles and nested fibroblasts reminiscent of reticular dermis. A transient inflammatory reaction was observed, consistent with the expected healing events.Use of autologous dermis as a filler substance for both aesthetic

2013 Plastic and reconstructive surgery

134. A blanching technique for intradermal injection of the hyaluronic acid Belotero. (Abstract)

A blanching technique for intradermal injection of the hyaluronic acid Belotero. With the proliferation of dermal fillers in the aesthetic workplace have come instructions from various manufacturers regarding dermal placement. Determination of injection needle location in the dermis has in large part been based on physician expertise, product and needle familiarity, and patient-specific skin characteristics. An understanding of the precise depth of dermal structures may help practitioners (...) improve injection specificity. Unlike other dermal fillers that suggest intradermal and deep dermal injection planes, a new hyaluronic acid with a cohesive polydensified matrix may be more appropriate for the superficial dermis because of its structure and its high degree of integration into the dermis. To that end, the authors designed a small study to quantify the depth of the superficial dermis by means of ultrasound and histology. Using ultrasound resources, the authors determined the depths

2013 Plastic and reconstructive surgery

135. Evaluation of the efficacy and safety of a lidocaine and tetracaine (7%/7%) cream for induction of local dermal anesthesia for facial soft tissue augmentation with hyaluronic Acid. (Abstract)

Evaluation of the efficacy and safety of a lidocaine and tetracaine (7%/7%) cream for induction of local dermal anesthesia for facial soft tissue augmentation with hyaluronic Acid. Injection of dermal fillers for soft tissue augmentation is a minimally invasive cosmetic procedure with growing popularity. However, patients often express concern about pain with such procedures. A topical anesthetic cream formulated with lidocaine/tetracaine 7%7% was approved by the United States Food and Drug (...) Administration in 2006 and recently reintroduced to the market for use during superficial dermatological procedures. A Phase 3 study was conducted to assess the efficacy and safety of lidocaine/tetracaine 7%7% cream versus placebo cream when used to induce local dermal anesthesia during injections with hyaluronic acid. Mean visual analog scale scores significantly favored lidocaine/tetracaine 7%7% cream. A significant percent of subjects also indicated that lidocaine/tetracaine 7%7% cream provided adequate

2014 The Journal of clinical and aesthetic dermatology Controlled trial quality: uncertain

136. Commentary: subcision versus dermal collagen filler for acne scars. (Abstract)

Commentary: subcision versus dermal collagen filler for acne scars. 21481061 2011 06 16 2011 04 12 1524-4725 37 4 2011 Apr Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg Commentary: subcision versus dermal collagen filler for acne scars. 432 10.1111/j.1524-4725.2011.01938.x Wasserman Daniel I DI Total Skin & Beauty Dermatology Center, Birmingham, Alabama, USA. dwass76@yahoo.com Monheit Gary D GD eng Comment Journal Article United (...) States Dermatol Surg 9504371 1076-0512 9007-34-5 Collagen IM Dermatol Surg. 2011 Apr;37(4):426-31 21388487 Acne Vulgaris complications Cicatrix etiology surgery Collagen administration & dosage Humans Injections Rhytidoplasty methods 2011 4 13 6 0 2011 4 13 6 0 2011 6 17 6 0 ppublish 21481061 10.1111/j.1524-4725.2011.01938.x

2011 Dermatologic Surgery

137. A comparison of the efficacy, safety, and longevity of two different hyaluronic acid dermal fillers in the treatment of severe nasolabial folds: a multicenter, prospective, randomized, controlled, single-blind, within-subject study. Full Text available with Trip Pro

effectiveness, safety, and longevity; however, this requires confirmation in the clinic.To compare the efficacy, safety, and longevity of two distinct HA-based dermal fillers in the correction of severe nasolabial folds (NLFs), a 24 mg/mL smooth gel (Juvederm ULTRA PLUS™ [JUP]) and a 20 mg/mL particulate gel (Perlane(®) [PER]) were injected in a total of 80 normal, healthy subjects using a split face design and were followed for 12 months in this prospective, randomized, controlled, multicenter study.Both (...) A comparison of the efficacy, safety, and longevity of two different hyaluronic acid dermal fillers in the treatment of severe nasolabial folds: a multicenter, prospective, randomized, controlled, single-blind, within-subject study. Commercially available hyaluronic acid (HA)-based fillers have distinct physicochemical properties related to their specific manufacturing technology, including HA concentration, cross-linking percentage, and particle size. These factors may determine treatment

2011 Clinical, cosmetic and investigational dermatology Controlled trial quality: uncertain

138. Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of severe nasolabial lines - 6-month interim results of a randomized, evaluator-blinded, intra-individual comparison study. (Abstract)

Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of severe nasolabial lines - 6-month interim results of a randomized, evaluator-blinded, intra-individual comparison study. Hyaluronic acid (HA) fillers are frequently used for the correction of facial soft tissue defects.To compare the efficacy and safety of a novel HA filler, HA(E) (Emervel Deep), with those of HA(P) (Restylane Perlane) in the treatment of severe nasolabial folds (NLF).A split-face, randomized (...) at week 24; P=0.002). Similar volume of both products was injected at baseline and touch-up. Both fillers were well tolerated, with similar worst score distribution and mean score for erythema, edema/swelling, bruising, and pruritus. Significantly less severe pain/tenderness was reported with HA(E) than with HA(P) (P<0.05).The new HA filler HA(E) provides better efficacy and similar local tolerability compared with HA(P) 6 months after the treatment of severe NLF.© 2011 Wiley Periodicals, Inc.

2011 Journal of cosmetic dermatology Controlled trial quality: uncertain

139. Comparative study of a new dermal filler Uma Jeunesse® and Juvéderm®. (Abstract)

Comparative study of a new dermal filler Uma Jeunesse® and Juvéderm®. Innovation in technology has resulted in the emergence of better, longer-lasting hyaluronic acid implants with fewer side effects. The new dermal implant Uma Jeunesse® was compared to Juvéderm® in this split-face study.Uma Jeunesse® is crosslinked with butanediol diglycidyl ether (BDDE) using a new crosslinking technology. Uma Jeunesse® and Juvéderm® Ultra 3 were injected in a split-face study on 17 healthy volunteers (...) Jeunesse® than Juvéderm(®) . After 9 months of follow-up, Uma Jeunesse® lasted in tissues for longer as compared to Juvéderm(®) even in patients injected for the first time (P<0.0001). Patient acceptability rate of Uma Jeunesse® was also much higher. Perception of pain during injection was lesser with Juvéderm® probably because of the presence of lidocaine.The new dermal implant Uma Jeunesse® is a safe and patient-friendly product which resides in the tissues for longer with maintenance of aesthetic

2011 Journal of cosmetic dermatology Controlled trial quality: uncertain

140. Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of moderate nasolabial folds: 6-month interim results of a randomized, evaluator-blinded, intra-individual comparison study. (Abstract)

Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of moderate nasolabial folds: 6-month interim results of a randomized, evaluator-blinded, intra-individual comparison study. Hyaluronic acid (HA) fillers such as Restylane(®) are frequently used for the correction of facial soft tissue defects.To compare the efficacy and safety of a novel HA filler, Emervel(®) Classic, with those of Restylane in the treatment of moderate nasolabial folds.This was a split-face (...) are reported. At week 24, the mean improvement in WSRS from baseline was 0.83 ± 0.51 for Emervel Classic, similar to that for Restylane (0.90 ± 0.57). A similar volume of both fillers was injected. Most local tolerability events were mild and transient. Erythema, oedema/swelling and pain/tenderness were significantly less severe and disappeared faster with Emervel Classic than with Restylane (at least p < 0.05).Emervel Classic provides similar efficacy and better overall local tolerability compared

2011 Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>